Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression

Warburg O. On the origin of cancer cells.Science 1956; 123: 309–314.

Brown RS, Wahl RL. Over expression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study.Cancer 1993; 72: 2979–2985.

Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors.J Nucl Med 1998; 39: 1727–1735.

Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2- fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture.Cancer Res 1999; 59: 4709–4714.

Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models.J Nucl Med 2001; 42: 1551–1555.

McAteer D, Wallis F, Couper G, Norton M, Welch A, Bruce D, et al. Evaluation of18F-FDG positron emission tomography in gastric and oesophageal carcinoma.Br J Radiol 1999; 72: 525–529.

Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.J Nucl Med 1994; 35: 1965–1969.

Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography.Hepatology 1998; 28: 700–706.

Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, et al. F-18 fluorodeoxyglucose PETin vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.Radiology 1994; 192: 79–86.

Gupta NC, Falk PM, Frank AL, Thorson AM, Frick MP, Bowman B. Pre-operative staging of colorectal carcinoma using positron emission tomography.NebrMed J 1993; 78: 30–35.

Ishizu K, Sadato N, Yonekura Y, Nishizawa S, Magata Y, Tamaki N, et al. Enhanced detection of brain tumors by [l8F]fluorodeoxyglucose PET with glucose loading.J Comput Assist Tomogr 1994; 18: 12–15.

Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E, et al. Metabolic imaging of human extremity musculoskeletal tumors byPET.J NuclMed 1988; 29:181–186.

Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study.J Nucl Med 1990; 31: 1927–1932.

Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]- fluoro-2-deoxy-D-glucose.Radiology 1991; 179: 765–770.

Annovazzi A, Peeters M, Maenhout A, Signore A, Dierckx R, Van De Wiele C. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract.Gastroenterology 2003; 125: 1235–1245.

Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings.Eur J Nucl Med Mol Imaging 2003; 30: 288–295.

Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al. Evaluation of18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer.J Nucl Med 2003; 44: 690–699.

Kim WS, Kim YY, Jang SJ, Kimm K, Jung MH. Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma.J Korean Med Sci 2000; 15: 420–424.

Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival.Cancer 2001; 92: 634–641.

Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer.World J Surg 2004; 283: 247–253.

Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition—.Gastric Cancer 1998; 1:10–24.

Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S. p53 Mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer.Int J Cancer 1993; 54: 759–764.

Ueyama T, Tsuneyoshi M. Poorly differentiated solid type adenocarcinomas in the stomach: a clinicopathologic study of 71 cases.J Surg Oncol 1992; 51: 81–88.

Yokota T, Kunii Y, Saito T, Teshima S, Yamada Y, Takahashi M, et al. Poorly differentiated, solid-type adeno-carcinoma of the stomach.Ups J Med Sci 1999; 104: 207–216.

Fiocca R, Luinetti O, Villani L, Mastracci L, Quilici P, Grillo F, et al. Molecular mechanisms involved in the pathogenesis of gastric carcinoma: interactions between genetic alterations, cellular phenotype and cancer histotype.Hepato-Gastroenterology 2001; 48: 1523–1530.

Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours.Nature 1996; 379: 88–91.

Dang CV, Semenza GL. Oncogenic alterations of metabolism.Trends Biochem Sci 1999; 2: 68–72.

Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53.J Biol Chem 1997; 36: 22776–22780.

Smith TA. Mammalian hexokinases and their abnormal expression in cancer.Br J Biotned Sci 2000; 2: 170–178.